Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, olaparib (Lynparza®) cannot be endorsed for use within NHS Wales as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. |
||
|
||
Medicine details |
||
| Medicine name | olaparib (Lynparza®) | |
| Formulation | 100 mg and 150 mg film-coated tablet | |
| Reference number | 3262 | |
| Indication | Monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen |
|
| Company | AstraZeneca UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 17/03/2021 | |